CXCL10 and COVID-19: A report demonstrated that CXCL10 (IP-10) inhibits endothelial recovery independently of any other inflammatory factor, and anti-CXCL10 antibody is under validation in a clinical trial to prevent cardiovascular events (Lupieri et al. 2020) because the more severe the COVID-19 patient, the higher the serum IP-10 level.